Drugs / Montanide Vaccine
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02334735 Comparator | Jul 2015 → Jul 2020 | melanoma | Nina Bhardwaj | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Montanide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02334735 ↗ |
| Modality | Vaccine | “Vaccine consisting of NY-ESO-1 peptide, Melan-A/MART-1 peptide, and KLH” NCT02334735 ↗ |
| Route | Subcutaneous | “administered subcutaneously as a single vaccine product” NCT02334735 ↗ |